The clock is ticking on the biggest financial event in 20 years.
And if you want to take advantage, you must position yourself before 2020 comes to an end…
There’s going to be some huge winners… including a company I think could easily go up 10x, maybe more.
It’s a small, lesser-known biotech stock that’s taking the health care sector by storm right now.
In the time of COVID-19, it’s seeing huge breakthroughs in some of the deadliest diseases that have plaguing us for decades… it’s not just jumping onto the bandwagon… it’s actually innovating, and the stock price reflects that.
I’m more bullish on biotech right now than I have been in my entire career.
Last December, I announced that 2020 would be the Year of Biotech.
Now, I’m upping my prediction to say that we’re actually in the Decade of Biotech.
Some of the biggest all-time high wins of my entire track record have been in biotech.
Allergan, up as high as 1,051%, Insulet, 1,411%, Dexcom over 3,400% – the list goes on and on.
What I love about this stock: even though it is a smaller mid-cap biotech stock… it already has revenue. It’s not just a flash in the pan. It has some real money coming in… over $300 million last year.
And by 2024, revenue is projected to shoot up to $2.5 billion dollars!
The company already has a number of drugs approved by the FDA and on the market… plus a pipeline of potential drugs that could send its stock price through the roof.
I’m talking about SEVERAL blockbuster drugs that analysts believe could bring in billions and billions of dollars.
And it's under the radar, not a lot of people talking about it… for now.
All of this makes it the perfect stock…
After running thousands of stocks through my 10X system and analysis, I've narrowed down 5 stocks that could soar anywhere from 500% to 1,000%… and this stock is one of them.
My newly released presentation gives you the stock symbol – plus details on the other four official recommendations that could soar 10X or more.
Simply enter your email address below to get immediate access to the presentation and you’ll also get ongoing updates from Breakthrough Investor.
By submitting your email address, you give Breakthrough Investor permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works
